Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$68.08 USD

68.08
171,040

+0.71 (1.05%)

Updated Sep 18, 2025 11:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Henry Schien Buys North American Rescue, Expands Medical Arm

by Zacks Equity Research

Henry Schien (HSIC) believes that acquisition of NAR's business will offer multiple growth opportunities and promising business synergies.

Zacks Equity Research

Moving Average Crossover Alert: Henry Schein

by Zacks Equity Research

Henry Schein, Inc. (HSIC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Zacks Equity Research

Henry Schein's (HSIC) Q4 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

Strength in Henry Schein's (HSIC) global Medical and Technology and Value-added Services businesses in Q4 is encouraging.

Zacks Equity Research

Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is well placed to gain from digitalization in the global dental market.

Zacks Equity Research

Henry Schein (HSIC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised)

by Zacks Equity Research

Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.

Zacks Equity Research

Near-Term Outlook for Dental Supplies Industry Looks Bright

by Zacks Equity Research

The wave of digital transformation is shaping the future of dental supply companies.

Zacks Equity Research

Henry Schein Animal Health Spin-Off Approaches, Cost Mounts

by Zacks Equity Research

Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.

Zacks Equity Research

Henry Schein (HSIC) Up 3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

What's in Store for Patterson Companies' (PDCO) Q2 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal Q2 earnings likely to be marred by a soft Dental unit; Animal Health looks promising.

Zacks Equity Research

Henry Schein's (HSIC) Q3 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

All four of Henry Schein's (HSIC) operating segments recording year-over-year growth in Q3 encourages us.

Zacks Equity Research

HSIC vs. WST: Which Stock Is the Better Value Option?

by Zacks Equity Research

HSIC vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips

by Zacks Equity Research

Integra LifeSciences' (IART) success with its channel expansion policy and Codman acquisition raise optimism on the stock.

Zacks Equity Research

Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is well placed to gain from the digitalization trend in the global dental market.

Zacks Equity Research

NuVasive (NUVA) Q3 Earnings Lag Estimates, Revenues Top Mark

by Zacks Equity Research

NuVasive (NUVA) registers balanced growth across its couple of business wings.

Zacks Equity Research

Chemed (CHE) Beats on Q3 Earnings, Raises 2018 Guidance

by Zacks Equity Research

The expansion in adjusted operating margin at Chemed (CHE) raises investor hopes on the stock.

Zacks Equity Research

Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cerner's (CERN) Q3 Earnings Match Estimates, Bookings Up Y/Y

by Zacks Equity Research

Cerner (CERN) gains from strong segmental revenues in the third quarter. Guidance for 2018 is impressive.

Zacks Equity Research

Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.

Zacks Equity Research

Stryker (SYK) Beats Q3 Earnings, Misses Sales Estimates

by Zacks Equity Research

Stryker's (SYK) Q3 results benefit from solid segmental performance. Also, the company sustained strength in International sales.

Zacks Equity Research

McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates

by Zacks Equity Research

McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.

Zacks Equity Research

Varian (VAR) Misses Earnings, Beats Revenue Estimates in Q4

by Zacks Equity Research

Varian's (VAR) Q4 results benefit from strong growth in Oncology Systems. Also, solid guidance boosts investors' optimism.

Zacks Equity Research

LabCorp (LH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

LabCorp (LH) might sustain its winning streak in third-quarter 2018 after having retained the same for the past few quarters. However, reimbursement pressure remains a concern.

Zacks Equity Research

Can Overall Growth Drive Thermo Fisher (TMO) Q3 Earnings?

by Zacks Equity Research

Thermo Fisher's (TMO) steadily strong analytical instrument business flaunts higher global demand.

Zacks Equity Research

HSIC or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HSIC vs. MMSI: Which Stock Is the Better Value Option?